The purpose of this study was to investigate the role of UGT1A1 polymorphism on the metabolism and pharmacokinetics of silymarin flavonolignans in patients with chronic HCV infection or nonalcoholic fatty liver disease (NAFLD). This evidence concerns the gene UGT1A1 and metabolic dysfunction-associated steatotic liver disease.